Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Apr 19;199(8):1037-40.
doi: 10.1084/jem.20040426. Epub 2004 Apr 12.

HIV transmission: closing all the doors

Affiliations
Review

HIV transmission: closing all the doors

Carl W Davis et al. J Exp Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Mucosal transmission of HIV. Mechanisms by which HIV may traverse the epithelium include tears in the epithelium, transcytosis, and interactions with Langerhans cells. In the submucosal space, HIV may infect local T cells or macrophages that express CD4 and either CXCR4 or CCR5. Virus entry can be blocked by agents that prevent binding of the viral Env protein to either CD4 or the viral coreceptor. However, HIV may still be able to establish an infection by binding to CD4, DC-SIGN, or other attachment molecules on the surface of DCs. HIV may be internalized by the DCs, and upon DC maturation (which may be triggered by HIV) and emigration from the submucosa via the lymphatics to regional lymph nodes, be delivered to an area rich in T cells but deficient in topically applied entry inhibitors. Thus, blocking direction infection of cells in the submucosa and interactions with DCs may be required to efficiently inhibit sexual transmission of HIV.

Comment on

Similar articles

Cited by

References

    1. Hu, Q., I. Frank, V. Williams, P. Watts, J.P. Moore, M. Pope, and R.J. Shattock. 2004. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J. Exp. Med. 199:1065–1075. - PMC - PubMed
    1. Van Damme, L., G. Ramjee, M. Alary, B. Vuylsteke, V. Chandeying, H. Rees, P. Sirivongrangson, L. Mukenge-Tshibaka, V. Ettiegne-Traore, C. Uaheowitchai, et al. 2002. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 360:971–977. - PubMed
    1. Nishimura, Y., T. Igarashi, N.L. Haigwood, R. Sadjadpour, O.K. Donau, C. Buckler, R.J. Plishka, A. Buckler-White, and M.A. Martin. 2003. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl. Acad. Sci. USA. 100:15131–15136. - PMC - PubMed
    1. Shibata, R., T. Igarashi, N. Haigwood, A. Buckler-White, R. Ogert, W. Ross, R. Willey, M.W. Cho, and M.A. Martin. 1999. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:204–210. - PubMed
    1. Mascola, J.R., M.G. Lewis, G. Stiegler, D. Harris, T.C. VanCott, D. Hayes, M.K. Louder, C.R. Brown, C.V. Sapan, S.S. Frankel, et al. 1999. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009–4018. - PMC - PubMed